The Alliance for Regenerative Medicine and 13 biotech companies released a statement outlining bioethical principles on genome editing, including opposition to modifications that can be passed to future generations.
Hospitals - especially in Europe - anticipate growing interest from international patients. But a wave of industry consolidation is debatable.
In this episode hear how improving benefit verification, prior authorizations, and patient affordability with smart integrations and real-time eligibility can streamline healthcare workflows.
CEO Arthur Tzianabos characterized the funding as “a huge leap forward for a new way to gene-edit for patients suffering with rare disorders.”
Its core science comes from Harvard Stem Cell Institute researcher Richard Gregory, who focuses on the function of miRNA in disease manifestation. We're guessing Homology Medicines is in this field as well.